Creating 100% Pathogen Free Environments

August 20, 2008 – Dr. Michael Shannon Appointed to Board of Directors

Dr. Michael E. Shannon Appointed to Board of Directors

SAN FRANCISCO, CALIFORNIA. - August 20, 2008 - Medizone International, Inc. (MZEI.PK) announces the appointment of Michael E. Shannon, M.A.,M.Sc.,M.D. to its' Board of Directors. Dr. Shannon received his medical degree from Queen's University in Canada, which included advanced training in surgery and sports medicine. He also holds post-graduate degrees in neurochemistry and physiology.

He has been actively engaged in applied medical research within these areas for over 27 years. He served in the Canadian Forces for 31 years retiring at the rank of Commodore (Brigadier General equivalent) as Deputy Surgeon General for Canada. During the first Gulf War, Dr. Shannon served as the senior medical liaison officer for all of the Canadian forces. In 1996 he assumed responsibilities within Health Canada for re-organizing the Canadian blood system. Working with both the provincial and federal governments he oversaw the development of a new corporate entity dedicated exclusively to the management of blood services in Canada. He was then appointed Director General for the Laboratory Centre for Disease Control, a position he held for three years.

In December 2000, Dr. Shannon left the Canadian federal government to pursue a new career in industry. In that capacity he simultaneously directed a phase III clinical trial in Canada, the United States and Great Britain for an artificial blood substitute product. Following completion of that work he was asked to accept a special assignment with the Canadian Federal Government Auditor General's office. His assignment being to conduct a cost benefit analysis of all government sponsored pharmacare programs and make recommendations directly to the Parliament of Canada. His assignment and presentation to Parliament on that project was completed in November 2004.

Dr. Shannon recently worked on a special project assignment as Senior Medical Advisor to the Canadian Public Health Agency. His assignment was to review and help rebuild the Canadian Public Health Agency's Emergency Medical Response Capacity. His work in that regard with the Canadian government was completed the end of July this year.

Internationally respected for his expertise, Dr. Shannon has been actively engaged in medical bio-oxidative based), research since 1987 and was directly responsible for the first human clinical trial to have ever been approved in North America which examined the efficacy of O 3 delivered via minor autohemotherapy in the treatment of AIDS. He was also responsible for several primate studies utilizing O 3 involving scientists from various departments within the Canadian Federal Government, as well as senior investigators from Medizone International and Cornell University.

Medizone's Chairman and CEO, Edwin Marshall commented; "On behalf of the members of the board and all of the Company's shareholders, we welcome Dr. Shannon to our Board of Directors. The wisdom and expertise Dr. Shannon brings to Medizone is unparalleled in the history of our company. I consider him a remarkable man and feel honored to be able to refer to him as a professional associate. This appointment signals an immense step forward in the reorganization of Medizone International.

Medizone International, Inc., is a research and development stage company engaged in the development of patented and unpatented technologies and protocols for O3 based bio-oxidative treatment of diseases caused by lipid enveloped viruses, including Acquired Immune Deficiency Syndrome (AIDS), Hepatitis B & C, and Herpes, the decontamination of blood, blood products and veterinarian serum products, and the treatment of external pathogenic conditions.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.

For more information contact:
Medizone International, Inc.
(415) 868-0300
Web site: www.medizoneint.com
Email: operations@medizoneint.com

Contact:

Medizone International, Inc. (MZEI.OB)

4000 Bridgeway, Suite 401,
Sausalito, CA 94965

Telephone: 415-331-0303

Email
: operations@medizoneint.com

Investor Relations:

John Pentony

Investor Relations,
Medizone International, Inc.

Telephone: (415) 331-0202

E: j.pentony@medizoneint.com

Media Contact:

Gary Hanauer

Media Relations,
Medizone International, Inc.

Telephone: (510) 686-1238

E: GarHan@aol.com